JAGUAR HEALTH INC (JAGX) Stock Price & Overview
NASDAQ:JAGX • US47010C8881
Current stock price
The current stock price of JAGX is 0.4075 USD. Today JAGX is up by 0.37%. In the past month the price decreased by -19.57%. In the past year, price decreased by -92.63%.
JAGX Key Statistics
- Market Cap
- 5.061M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -37.61
- Dividend Yield
- N/A
JAGX Stock Performance
JAGX Stock Chart
JAGX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to JAGX. When comparing the yearly performance of all stocks, JAGX is a bad performer in the overall market: 99.12% of all stocks are doing better.
JAGX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to JAGX. JAGX may be in some trouble as it scores bad on both profitability and health.
JAGX Earnings
JAGX Forecast & Estimates
7 analysts have analysed JAGX and the average price target is 16.32 USD. This implies a price increase of 3904.91% is expected in the next year compared to the current price of 0.4075.
For the next year, analysts expect an EPS growth of 76.14% and a revenue growth 30% for JAGX
JAGX Groups
Sector & Classification
JAGX Financial Highlights
Over the last trailing twelve months JAGX reported a non-GAAP Earnings per Share(EPS) of -37.61. The EPS increased by 31.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -139.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
JAGX Ownership
JAGX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.96 | 871.596B | ||
| JNJ | JOHNSON & JOHNSON | 18.77 | 578.307B | ||
| MRK | MERCK & CO. INC. | 23.24 | 296.588B | ||
| PFE | PFIZER INC | 9.13 | 154.211B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.15 | 118.584B | ||
| ZTS | ZOETIS INC | 17.13 | 51.124B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.43 | 28.162B | ||
| VTRS | VIATRIS INC | 5.59 | 16.197B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 11.987B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.45B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.08B | ||
| CORT | CORCEPT THERAPEUTICS INC | 80.48 | 4.646B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JAGX
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
Company Info
IPO: 2015-05-13
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Phone: 13026587581
JAGUAR HEALTH INC / JAGX FAQ
What does JAGX do?
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. The company has an exclusive distribution agreement for the sale of Gelclair. The company is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.
What is the stock price of JAGUAR HEALTH INC today?
The current stock price of JAGX is 0.4075 USD. The price increased by 0.37% in the last trading session.
Does JAGUAR HEALTH INC pay dividends?
JAGX does not pay a dividend.
What is the ChartMill rating of JAGUAR HEALTH INC stock?
JAGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does JAGUAR HEALTH INC belong to?
JAGUAR HEALTH INC (JAGX) operates in the Health Care sector and the Pharmaceuticals industry.
How many employees does JAGUAR HEALTH INC have?
JAGUAR HEALTH INC (JAGX) currently has 49 employees.
What is the next earnings date for JAGX stock?
JAGUAR HEALTH INC (JAGX) will report earnings on 2026-05-13.